- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Moderna Inc (MRNA)
51.23
-1.62(-3.07%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
50.61
53.49
52 wk Range
22.28
59.55
MRNA Comments
Compiled here, all relevant comments and discussions regarding the MRNA stock. Please note that all comments included here have met Investing.com's Comment Guidelines.
We can not exclude that Moderna has leveraged Phase 2 results with AI to refine neoantigen selection and manufacturing, potentially boosting Phase 3 oncology trial outcomes for its innovative mRNA cancer vaccines like inti-meran, leading to possible higher efficacy of the new products
Moderna's stock has surged about 90% since the start of the year, and this ongoing positivity might be tied to high expectations for positive oncology trial results from their new pipeline products.
How's the EpsTeen clot shot business going these days. Any plandemics in the works again.
started plumbing after Trump became president and he was supposed to get rid of it
The continued rise of this stock ahead of the phase 3 data readout for the new cancer vaccines suggests that the positive signals already seen in phase 2 may have a good chance to be confirmed. It also hints that the data could be strong enough to support an emergency procedure for making these new drugs quickly available.
👍
Moderna botomed few months ago,now started pillars making the foundation strong..i want to sell my 450shares at 110..and wait for another climb… and its upcoming quarter results .I wznt to see -1.50 in upcoming quarter if exceeded..will poured more stocks on it…
Bgates and drfauci were very based, friends
MRNA always respects gap fills.
Moderna's stock is poised for potential upside in 2026, aligned with expected readouts from key studies like the Phase 3 intismeran autogene (mRNA-4157) trial in melanoma, Phase 2b five-year data, and norovirus Phase 3 results. The company forecasts up to 10% revenue growth, fueled by international sales, vaccine approvals (e.g., flu mRNA-1010, combo mRNA-1083), and oncology pipeline progress, which could drive positive valuation impacts if successful. While forecasts vary—some predict modest gains around $30-45, others see surges to $300+ on strong data—clinical successes remain pivotal for lifting MRNA's value.
Moving towards $60
$41.83 (+6%)
Investing in Moderna is just throwing money down the drain. $25 stock.
selling
incredible movement, buy or sell?
Heading to $60
Nasty genetic goop turning humans into lab rats. No one wants to be a GMO
$32.28 (-7%)
winter is coming
Site is biased, Moderna us headed towards 200
Tbis sure lues, Moderna is headed towards 200+
Market seems to know RFK and his cronies are full of s... !
insider assisted shorting is illegal....
$24.18 (-7%)
Should the company consider buying back shares when it is too low to show its confidence in its future strategy?
...
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.